🧾 What This Document Is

This is a quarterly earnings report (Form 8-K with an exhibit) for Neogen Corporation. It's like a "report card" for the company's third fiscal quarter, which ended on February 28, 2026. Companies are required to file these with the SEC to update investors on their financial health and major business developments.

🏢 What The Company Does

👉 In simple terms, Neogen is a safety science company. They develop and sell products that help ensure the safety of food and animals. Think of them as a provider of test kits and solutions that detect contaminants in food and protect livestock and pets. They operate in two main segments: Food Safety and Animal Safety.

💰 Financial Highlights: A Mixed Quarter

The quarter was a story of two different businesses pulling in opposite directions.

Food Safety: The Steady Engine

Revenue: $156.7 million, up 2.6% from last year.
Core Growth (a metric that smooths out currency effects): +4.0%.
Why it matters: This is Neogen's larger and more stable segment. Growth here, especially in "Indicator Testing & Culture Media" (up 11%), shows underlying demand for their core food safety products is solid.

Animal Safety: The Problem Child

Revenue: $54.5 million, down a steep 20.1% from last year.
Core Growth: -8.7%.
Why it matters: The big drop was blamed on third-party supplier problems. This is a major headwind and dragged down the company's total revenue. Management says these are "transient issues," but they hurt the quarter badly.

The Bottom Line: Loss vs. Profit

GAAP Net Loss: -$17.0 million (a loss of $0.08 per share).
Adjusted Net Income: +$19.4 million (a profit of $0.09 per share).
Why it matters: The "GAAP" number is the official accounting loss, hit by one-time costs. The "Adjusted" number strips those out to show what the core business earned. This gap tells you there were significant unusual expenses this quarter.

🚀 Key Strategic Moves

Neogen is actively reshaping its business.

Petrifilm® Manufacturing Transition: They are moving production of this key product line to a new process. It's on track for completion in November 2026. This is a huge, disruptive project aimed at improving efficiency long-term but causing duplicate costs now.
Selling the Genomics Business: Neogen agreed to sell its global Genomics unit to Zoetis Inc. for $160 million. After costs, they expect about $140 million in cash. This move will simplify their business and pay down debt.

📦 Financial Position & Guidance

Cash Flow: They generated $22.7 million in cash from operations and $11.1 million in free cash flow. This is a good sign of underlying cash generation.
Debt Goal: The cash from the Genomics sale will help them achieve a net debt-to-Adjusted EBITDA ratio of less than 3 times by the end of 2026. This is a key metric for financial health.
Updated Guidance (The Outlook): They raised their full-year revenue forecast to $857-$860 million (from $845-$855 million). They kept their Adjusted EBITDA guidance steady at ~$175 million.
Why it matters: Raising the revenue outlook despite a tough quarter signals confidence in a rebound, likely from solving the supply issues and the Petrifilm transition completing.

⚖️ Big Picture: Strengths & Risks

👍 Strengths

Market Leader in Food Safety: A strong, growing core business with resilient demand.
Active Portfolio Management: Selling the Genomics unit focuses the company and provides cash.
Cost Control: Delivered solid Adjusted EBITDA margins (22.8%) despite revenue pressure, showing discipline.

⚠️ Risks

Supplier Dependency: The Animal Safety stumble shows vulnerability to third-party suppliers.
Execution Risk: The complex Petrifilm manufacturing transition must finish on time and without further hiccups.
Integration & Turnaround: The company is undergoing a major "strategic transformation." Successfully executing all these changes at once is a big challenge.

🔮 What's Next

The story for the next few quarters is clear: Execute the turnaround. The key milestones to watch are:

Fixing the Animal Safety supply chain.
Successfully completing the Petrifilm transition by November 2026.
Closing the Genomics sale and using the cash to strengthen the balance sheet.
Demonstrating that the new "solutions-based selling" strategy can drive growth.

🧠 The Analogy

Neogen is like a homeowner remodeling their kitchen while also fixing a burst pipe in the basement. The kitchen remodel (Petrifilm transition, new sales strategy) is a noisy, messy investment for the future. The burst pipe (Animal Safety supplier issue) is an urgent, unplanned crisis that flooded the current quarter. The good news? They've also decided to sell their old car (Genomics business) to pay for the repairs and keep the project on track.

🧩 Final Takeaway

Neogen's quarter was defined by a temporary supplier crisis in Animal Safety, but the underlying Food Safety business is growing, and management is aggressively restructuring through the Petrifilm transition and a business sale. The raised revenue guidance suggests they believe the worst of the temporary problems is behind them.

NEOGEN CORP — 8-K Filing